靶向 TIGIT：肝外胆管癌免疫治疗新希望 —— 解读《TIGIT expression in extrahepatic cholangiocarcinoma and its impact on CD8 + T cell exhaustion: implications for immunotherapy》 陆军军医大学第一附属医院肝胆外科的 Tengqian Tang 等研究人员，在《Cell ...

TIGIT靶点，曾被誉为“下一个PD-1”，在免疫治疗领域备受瞩目。然而，其研发之路却充满坎坷，众多药企纷纷折戟。近期，阿斯利康的PD-1/TIGIT双抗药物Rilvegostomig启动了头对头帕博利珠单抗（K药）的III期研究，为TIGIT靶点带 ...

CD8-positive T cells are a critical subpopulation of MHC class I-restricted T cell and are mediators of adaptive immunity. They include cytotoxic T cells, which are important for killing cancerous ...

Like PD-1/PD-L1, TIGIT is thought to act as a molecular brake that stops T-cells from attacking tumours, and tiragolumab has been leading the pack among drugs targeting the immune checkpoint.

This discovery sheds light on how tissue-resident memory CD8 T cells adapt to their location in the body, ensuring a coordinated and effective immune response and how microenvironments and ...

Roche is one of the leaders in research in to TIGIT – short for T Cell Immunoreceptor with IG and ITIM Domains – and is developing a combination of TIGIT-targeting tiragolumab and its PD-L1 ...

Initial data demonstrate a highly differentiated clinical pharmacodynamic profile with unprecedented levels of selective CD8+ T cell activation as well as initial evidence of anti-tumor effect ...